Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."